GlassScriptPhysician profile
Kathryn Herrera
NPI 1568102861
$10,867.01
in general payments reported to CMS, 2019-2025
22 companies · $3,705 in 2025
The $3,705 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,197 · 2023: $2,873 · 2024: $3,092 · 2025: $3,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,419 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,418.61 |
| Education | $251.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,806.98 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,508.09 | 2022-2025 | Caplyta |
| Alkermes, INC. | $1,322.43 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $1,283.17 | 2023-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $842.98 | 2022-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Indivior INC. | $762.43 | 2022-2024 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $731.94 | 2022-2025 | Ingrezza |
| Abbvie INC. | $668.76 | 2022-2025 | |
| Lundbeck LLC | $574.70 | 2022-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $313.07 | 2023-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $231.93 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $208.48 | 2022-2025 | Trintellix |
| Axsome Therapeutics, INC. | $198.55 | 2024-2025 | Auvelity |
| Bausch Health US, LLC | $174.31 | 2022-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $63.13 | 2024-2025 | Azstarys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $44.20 | 2022 | |
| Arbor Pharmaceuticals, INC. | $26.72 | 2022 | |
| Acadia Pharmaceuticals INC | $26.05 | 2024 | Nuplazid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.69 | 2025 | Abilify Maintena |
| Catalyst Pharmaceuticals, INC. | $21.31 | 2023 | Fycompa |
| Ironshore Pharmaceuticals INC. | $17.93 | 2023 | Jornay Pm |
| Noven Therapeutics, LLC | $16.16 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.